Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the breast cancer drug market in China will grow from $165 million in 2008 to $298 million in 2013. This growth will be fueled by a rising number of incident cases, greater access to medical care, growing individual wealth and purchasing power and expanded use of novel therapies.

"The aging and urbanization among the Chinese population are major contributors to the increasing incidence of breast cancer," stated Jing Wu, M.S., MBA. "The aging population will result in an increase of 70 percent in cases of postmenopausal breast cancer, from 95,860 to 162,780, from 2008 to 2018. Urban Chinese women have a higher risk of breast cancer, most likely due to this population's adoption of a more Westernized lifestyle."

The new Emerging Markets report entitled Breast Cancer in China also finds that Chinese oncologists anticipate an increase in the use of targeted therapy in breast cancer treatment during the 2008 - 2013 forecast period. Western brands that will benefit from this trend include Roche's Herceptin, GlaxoSmithKline's Tykerb and Roche's Avastin. Cost is the biggest barrier that prevents more eligible patients from being treated with these agents.

The report contains primary research of physicians and epidemiology in key pharmaceutical markets of China -- Beijing, Shanghai, Guangzhou -- and in the high-growth second-tier markets of Tianjin, Wuhan, Nanjing, Hangzhou and Jinan.

About Emerging Markets Reports

Decision Resources is the FIRST and ONLY company to offer a syndicated report series for high-growth emerging markets with comprehensive disease-specific analysis. Each report assesses the commercial opportunity in the pharmaceutical market for a disease based on population demographics, economic development, disease epidemiology and changing physicians' practices.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  Gisselle Morales             Elizabeth Marshall   Decision Resources           Decision Resources, Inc.   781-296-2691                 781-296-2563 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources

CONTACT: Gisselle Morales of Decision Resources, +1-781-296-2691,, or Elizabeth Marshall of Decision Resources, Inc.,

Chronic Pain Drug Market Will Experience Modest Four Percent Annual Growth From 2008 to 2018

View Now